74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
English (International)
Altimmune Inc
Closed
3.54 0.85
Overview
Share price change
24h
Min
3.39
Max
3.74
Income | 3.1M -19M |
|---|---|
Sales | 5K |
Profit margin | -380,280 |
Employees | 59 |
EBITDA | 4.4M -18M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +220% upside |
Next Earnings | 12 May 2026 |
|---|
Market Cap | 171M 521M |
|---|---|
Previous open | 2.69 |
Previous close | 3.54 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Altimmune Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Altimmune Inc Forecast
Price Target
By TipRanks
220% upside
12 Months Forecast
Average 11.2 USD 220%
High 20 USD
Low 4.01 USD
Based on 6 Wall Street analysts offering 12 month price targets forAltimmune Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Live chat